YXYongna Xing

Yongna Xing

*This is an algorithmically generated author record based on publicly available information.

Yongna Xing has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • Kenneth A. Satyshur

    Department of Biomolecular Chemistry, University of Wisconsin-Madison, Madison, USA

    8 shared publications
  • Li Jiang

    McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin at Madison, School of Medicine and Public Health, Madison, WI, 53705, USA

    8 shared publications
  • Vitali Stanevich

    McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin at Madison, School of Medicine and Public Health, Madison, WI, 53705, USA

    8 shared publications
  • Cheng-Guo Wu

    McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin at Madison, School of Medicine and Public Health

    7 shared publications
  • Feng Guo

    McArdle Laboratory for Cancer Research, WIMR II 6451, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA

    6 shared publications
  • Aiping Zheng

    College of Agronomy, Sichuan Agricultural University, Chengdu, China

    5 shared publications

Latest Publications

  • Open Access

    B56δ long-disordered arms form a dynamic PP2A regulation interface coupled with global allostery and Jordan’s syndrome mutations

    by Cheng-Guo Wu, Vijaya K. Balakrishnan, Ronald A. Merrill, Pankaj S. Parihar, Kirill Konovolov, Yu-Chia Chen, Zhen Xu, Hui Wei, Ramya Sundaresan, Qiang Cui, et al.

    Intrinsically disordered regions (IDR) and short linear motifs (SLiMs) play pivotal roles in the intricate signaling networks governed by phosphatases and kinases. B56δ (encoded byPPP2R5D) is a regulatory subunit of protein phosphatase 2A (PP2A) with long IDRs that harbor a substrate-mimicking SLiM and multiple phosphorylation sites. De novo missense mutations inPPP2R5Dcause intellectual disabilities (ID), macrocephaly, Parkinsonism, and a broad range of neurological symptoms. Our single-particle cryo-EM structures of the PP2A-B56δ holoenzyme reveal that the long, disordered arms at the B56δ termini fold against each other and the holoenzyme core. This architecture suppresses both the phosphatase active site and the substrate-binding protein groove, thereby stabilizing the enzyme in a closed latent form with dual autoinhibition. The resulting interface spans over 190 Å and harbors unfavorable contacts, activation phosphorylation sites, and nearly all residues with ID-associated mutations. Our studies suggest that this dynamic interface is coupled to an allosteric network responsive to phosphorylation and altered globally by mutations. Furthermore, we found that ID mutations increase the holoenzyme activity and perturb the phosphorylation rates, and the severe variants significantly increase the mitotic duration and error rates compared to the normal variant.


  • Disease mutations and phosphorylation alter the allosteric pathways involved in autoinhibition of protein phosphatase 2A

    by Kirill A. Konovalov, Cheng-Guo Wu, Yunrui Qiu, Vijaya Kumar Balakrishnan, Pankaj Singh Parihar, Michael S. O’cOnnor, Yongna Xing, Xuhui Huang

    Mutations in protein phosphatase 2A (PP2A) are connected to intellectual disability and cancer. It has been hypothesized that these mutations might disrupt the autoinhibition and phosphorylation-induced activation of PP2A. Since they are located far from both the active and substrate binding sites, it is unclear how they exert their effect. We performed allosteric pathway analysis based on molecular dynamics simulations and combined it with biochemical experiments to investigate the autoinhibition of PP2A. In the wild type (WT), the C-arm of the regulatory subunit B56δ obstructs the active and substrate binding sites exerting a dual autoinhibition effect. We find that the disease mutant, E198K, severely weakens the allosteric pathways that stabilize the C-arm in the WT. Instead, the strongest allosteric pathways in E198K take a different route that promotes exposure of the substrate binding site. To facilitate the allosteric pathway analysis, we introduce a path clustering algorithm for lumping pathways into channels. We reveal remarkable similarities between the allosteric channels of E198K and those in phosphorylation-activated WT, suggesting that the autoinhibition can be alleviated through a conserved mechanism. In contrast, we find that another disease mutant, E200K, which is in spatial proximity of E198, does not repartition the allosteric pathways leading to the substrate binding site; however, it may still induce exposure of the active site. This finding agrees with our biochemical data, allowing us to predict the activity of PP2A with the phosphorylated B56δ and provide insight into how disease mutations in spatial proximity alter the enzymatic activity in surprisingly different mechanisms.


  • Open Access

    Extended regulation interface coupled to the allosteric network and disease mutations in the PP2A-B56δ holoenzyme

    by Cheng-Guo Wu, Vijaya Kumar Balakrishnan, Pankaj Singh Parihar, Kirill Konovolov, Yu-Chia Chen, Ronald A Merrill, Hui Wei, Bridget Carragher, Ramya Sundaresan, Qiang Cui, et al.

    An increasing number of mutations associated with devastating human diseases are diagnosed by whole-genome/exon sequencing. Recurrent de novo missense mutations have been discovered in B56δ (encoded by PPP2R5D ), a regulatory subunit of protein phosphatase 2A (PP2A), that cause intellectual disabilities (ID), macrocephaly, Parkinsonism, and a broad range of neurological symptoms. Single-particle cryo-EM structures show that the PP2A-B56δ holoenzyme possesses closed latent and open active forms. In the closed form, the long, disordered arms of B56δ termini fold against each other and the holoenzyme core, establishing dual autoinhibition of the phosphatase active site and the substrate-binding protein groove. The resulting interface spans over 190 Å and harbors unfavorable contacts, activation phosphorylation sites, and nearly all residues with ID-associated mutations. Our studies suggest that this dynamic interface is close to an allosteric network responsive to activation phosphorylation and altered globally by mutations. Furthermore, we found that ID mutations perturb the activation phosphorylation rates, and the severe variants significantly increase the mitotic duration and error rates compared to the wild variant.

  • Open Access

    Coupling to short linear motifs creates versatile PME-1 activities in PP2A holoenzyme demethylation and inhibition

    by Yitong Li, Vijaya Kumar Balakrishnan, Michael Rowse, Cheng-Guo Wu, Anastasia Phoebe Bravos, Vikash K Yadav, Ylva Ivarsson, Stefan Strack, Irina V Novikova, Yongna Xing

    Protein phosphatase 2A (PP2A) holoenzymes target broad substrates by recognizing short motifs via regulatory subunits. PP2A methylesterase 1 (PME-1) is a cancer-promoting enzyme and undergoes methylesterase activation upon binding to the PP2A core enzyme. Here, we showed that PME-1 readily demethylates different families of PP2A holoenzymes and blocks substrate recognition in vitro. The high-resolution cryoelectron microscopy structure of a PP2A-B56 holoenzyme–PME-1 complex reveals that PME-1 disordered regions, including a substrate-mimicking motif, tether to the B56 regulatory subunit at remote sites. They occupy the holoenzyme substrate-binding groove and allow large structural shifts in both holoenzyme and PME-1 to enable multipartite contacts at structured cores to activate the methylesterase. B56 interface mutations selectively block PME-1 activity toward PP2A-B56 holoenzymes and affect the methylation of a fraction of total cellular PP2A. The B56 interface mutations allow us to uncover B56-specific PME-1 functions in p53 signaling. Our studies reveal multiple mechanisms of PME-1 in suppressing holoenzyme functions and versatile PME-1 activities derived from coupling substrate-mimicking motifs to dynamic structured cores.


  • Open Access

    Coupling to short linear motifs creates versatile PME-1 activities in PP2A holoenzyme demethylation and inhibition

    by Yitong Li, Vijaya Kumar Balakrishnan, Michael Rowse, Cheng-Guo Wu, Anastasia Phoebe Bravos, Vikash K Yadav, Ylva Ivarsson, Stefan Strack, Irina V Novikova, Yongna Xing

    Protein phosphatase 2A (PP2A) holoenzymes target broad substrates by recognizing short motifs via regulatory subunits. PP2A methylesterase 1 (PME-1) is a cancer-promoting enzyme and undergoes methylesterase activation upon binding to the PP2A core enzyme. Here we showed that PME-1 readily demethylates different families of PP2A holoenzymes and blocks substrate recognition in vitro . The high-resolution cryo-EM structure of a PP2A-B56 holoenzyme-PME-1 complex reveals that PME-1 disordered regions, including a substrate-mimicking motif, tether to the B56 regulatory subunit at remote sites. They occupy the holoenzyme substrate-binding groove and allow large structural shifts in both holoenzyme and PME-1 to enable multi-partite contacts at structured cores to activate the methylesterase. B56-interface mutations selectively block PME-1 activity toward PP2A-B56 holoenzymes and affect the methylation of a fraction of total cellular PP2A. The B56-interface mutations allow us to uncover B56-specific PME-1 functions in p53 signaling. Our studies reveal multiple mechanisms of PME-1 in suppressing holoenzyme functions and versatile PME-1 activities derived from coupling substrate-mimicking motifs to dynamic structured cores.

  • Small-molecule inhibitors that disrupt the MTDH–SND1 complex suppress breast cancer progression and metastasis

    by Minhong Shen, Yong Wei, Hahn Kim, Liling Wan, Yi-Zhou Jiang, Xiang Hang, Michael Raba, Stacy Remiszewski, Michelle Rowicki, Cheng-Guo Wu, et al.

    Metastatic breast cancer is a leading health burden worldwide. Previous studies have shown that metadherin (MTDH) promotes breast cancer initiation, metastasis and therapy resistance; however, the therapeutic potential of targeting MTDH remains largely unexplored. Here, we used genetically modified mice and demonstrate that genetic ablation of Mtdh inhibits breast cancer development through disrupting the interaction with staphylococcal nuclease domain-containing 1 (SND1), which is required to sustain breast cancer progression in established tumors. We performed a small-molecule compound screening to identify a class of specific inhibitors that disrupts the protein–protein interaction (PPI) between MTDH and SND1 and show that our lead candidate compounds C26-A2 and C26-A6 suppressed tumor growth and metastasis and enhanced chemotherapy sensitivity in preclinical models of triple-negative breast cancer (TNBC). Our results demonstrate a significant therapeutic potential in targeting the MTDH–SND1 complex and identify a new class of therapeutic agents for metastatic breast cancer.


  • Open Access

    Cryo-EM and cellular dissection uncover versatile PME-1 activities in PP2A holoenzyme demethylation and inhibition

    by Yongna Xing, Yitong Li, Michael Rowse, Cheng-Guo Wu, Anastasia Bravos, Yiva Ivarsson, Stefan Strack

    Protein phosphatase 2A (PP2A) methylesterase 1 (PME-1) is cancer-promoting but essential for development, and long-believed to remove carboxymethylation, a central modification, from the common PP2A core enzyme but not diverse holoenzymes that target broad cellular signaling by recognizing specific disordered motifs via regulatory subunits. On the contrary, our biochemical dissection and high-resolution cryo-EM structural analysis of a PP2A-B’ holoenzyme-PME-1 complex reveal that PME-1 disordered motifs, including phosphatase substrate-mimicking motifs, tether to the holoenzyme at remote sites, block its substrate binding, and allow large structural shifts in both holoenzyme and PME-1 to enable multiptle dynamic structured contacts and induce methylesterase activation toward the holoenzyme. PME-1 inhibitor and B’-interface mutations differentially modulate cellular PP2A methylation and allow us to uncover cellular PME-1 functions in AKT-p53 signaling. Our studies demonstrate how dynamic structured cores and disordered motifs create versatile activities and lay a foundation for investigating and targeting multifaceted activities toward broad PP2A complexes in cellular signaling.

  • Open Access

    Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR)

    by Seung-Hyeon Seok, Zhi-Xiong Ma, John B. Feltenberger, Hongbo Chen, Hui Chen, Cameron Scarlett, Ziqing Lin, Kenneth A. Satyshur, Marissa Cortopassi, Colin R. Jefcoate, et al.


  • Open Access

    Methylation-regulated decommissioning of multimeric PP2A complexes

    by Cheng-Guo Wu, Aiping Zheng, Li Jiang, Michael Rowse, Vitali Stanevich, Hui Chen, Yitong Li, Kenneth A. Satyshur, Benjamin Johnson, Ting-Jia Gu, et al.

    Dynamic assembly/disassembly of signaling complexes are crucial for cellular functions. Specialized latency and activation chaperones control the biogenesis of protein phosphatase 2A (PP2A) holoenzymes that contain a common scaffold and catalytic subunits and a variable regulatory subunit. Here we show that the butterfly-shaped TIPRL (TOR signaling pathway regulator) makes highly integrative multibranching contacts with the PP2A catalytic subunit, selective for the unmethylated tail and perturbing/inactivating the phosphatase active site. TIPRL also makes unusual wobble contacts with the scaffold subunit, allowing TIPRL, but not the overlapping regulatory subunits, to tolerate disease-associated PP2A mutations, resulting in reduced holoenzyme assembly and enhanced inactivation of mutant PP2A. Strikingly, TIPRL and the latency chaperone, α4, coordinate to disassemble active holoenzymes into latent PP2A, strictly controlled by methylation. Our study reveals a mechanism for methylation-responsive inactivation and holoenzyme disassembly, illustrating the complexity of regulation/signaling, dynamic complex disassembly, and disease mutations in cancer and intellectual disability.


  • Purification of Target Proteins from Native Tissues: CCT Complex from Bovine Testes and PP2Ac from Porcine Brains

    by Feng Guo, Nathan Wlodarchak, Patrick Menden, Yongna Xing

    Proteomics is a powerful approach for systematic identification and quantification of the entire proteome of a biological system (cell, tissue, organ, biological fluid, or organism) at specific time points ( http://www.nature.com ). Extracting and purifying target proteins from native tissues are essential steps for many aspects of proteomic studies. In this chapter, we will introduce the experimental procedures to obtain soluble proteins from two different tissues: (1) the CCT (cpn-containing TCP-1) complex from bovine testes and (2) the protein phosphatase 2A (PP2A) catalytic subunit (PP2Ac or C) from porcine brains. With these two examples, we would like to provide some general guidelines for researchers on how to extract and purify target proteins from specific tissues and extend these approaches to other proteins of interest.